Abstract
Ischemic heart disease (IHD) and systemic hypertension commonly coexist in a large number of patients, and the presence of hypertension is a risk factor for worsening IHD. A monotherapy that would effectively treat both is thus an attractive idea, and calcium antagonists have been evaluated in this role. Calcium antagonists exert therapeutic effects through a combination of actions, including systemic and peripheral vasodilation, negative inotropy, and reduced nodal conduction. In randomized, double-blind clinical trials, verapamil compares favorably with propranolol in the alleviation of angina and hypertension. Both diltiazem and nifedipine, as well as long-acting diltiazem, are also effective in treating the combined condition. In addition, each of these drugs enhances exercise tolerance and favors compliance with calcium antagonist therapy. Recent questions regarding the safety of this class of drug have tempered the enthusiasm for their use as first-line therapy in cardiovascular disease. In particular, short-acting dihydropyridine derivatives, including nifedipine and isradipine, may increase cardiovascular morbidity and mortality because of reflex sympathetic stimulation. The results of appropriately controlled, prospect...Continue Reading
References
Apr 1, 1975·Circulation·W B KannelT Gordon
Nov 23, 1976·The American Journal of Cardiology·W Hollander
Aug 1, 1978·American Heart Journal·K AokiK Takikawa
Jan 1, 1991·Journal of Cardiovascular Pharmacology·W H Frishman
Jan 1, 1988·Journal of Cardiovascular Pharmacology·W H Frishman, E J Lazar
Dec 6, 1985·The American Journal of Cardiology·R A O'Rourke
Dec 14, 1987·The American Journal of Cardiology·D T KawanishiR A O'Rourke
Feb 26, 1986·The American Journal of Cardiology·W H FrishmanN Klein
Dec 6, 1985·The American Journal of Cardiology·W H FrishmanJ Strom
Jul 1, 1969·Annals of Internal Medicine·W B KannelD Offutt
Jan 1, 1982·European Journal of Clinical Pharmacology·S E HustedO Lederballe Pedersen
Nov 1, 1982·The American Journal of Cardiology·W H FrishmanE H Sonnenblick
Sep 1, 1982·Circulation·N N SadickD T Kelly
Nov 13, 1995·Archives of Internal Medicine·T C Fagan
Nov 13, 1995·Archives of Internal Medicine·C D Furberg, B M Psaty
Sep 1, 1995·Circulation·C D FurbergJ V Meyer
Mar 1, 1995·Hypertension·V L BurtD Labarthe
Oct 1, 1995·Cardiovascular Drugs and Therapy·W C LittleM Nordlander
Jul 1, 1996·Journal of the American College of Cardiology·S BraunU Goldbourt
Sep 1, 1996·Circulation·B L RodriguezJ D Curb
Oct 10, 1996·The New England Journal of Medicine·M PackerD L DeMets
Jan 1, 1997·European Heart Journal
Citations
Aug 7, 2001·British Journal of Pharmacology·S Berjukow, S Hering
Mar 4, 2008·Biological & Pharmaceutical Bulletin·Daiki TakahashiShizuo Yamada
Jan 24, 2002·Japanese Heart Journal·M UchiyamaH Toyoshima
Feb 2, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Kacper DrużbickiJan Wąsicki
Jan 7, 2004·The American Journal of Medicine·Mark J EisenbergAlain N Bestawros
Nov 11, 1998·Journal of the American College of Cardiology·C J PepineP Zellig
Mar 11, 2006·Endocrinology·J HallC Peers